Skip to main content
Premium Trial:

Request an Annual Quote

Waters Reports Increased Income for Q2

NEW YORK, July 22 -Waters reported a net 7 percent revenue increase for the second quarter today, and an 11 percent increase in quarterly income.


The Milford, Mass-based company, which manufactures instruments for mass spectrometry, high performance liquid chromatography, and thermal analysis, reported sales of $231.8 million for the quarter, compared to $217.2 million for the year-ago period.


"Despite a slowdown in our research mass spectrometry product lines, we were able to meet our earnings projections primarily through steady overall HPLC growth, our global presence, and prudent expense management," said Douglas Berthiaume, Chairman, president, and CEO of Waters, in a statement.


The company's R&D expense totaled $13.8 million, compared to $12.6 million for the second quarter of 2002.

Waters' net income for the second quarter came to $42.1 million, compared to $37.9 million for the year-ago period.


At the end of the quarter, the company had $283.0 million in cash and cash equivalents.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.